- Home
- VNT vs SRRK Comparison
VNT vs SRRK Comparison
Compare VNT & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNT | SRRK |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | VNT | SRRK |
|---|---|---|
| Price | $37.18 | $47.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $46.11 | ★ $47.00 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | ★ 0.27% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $3,043,900,000.00 | N/A |
| Revenue This Year | $2.79 | N/A |
| Revenue Next Year | $3.27 | $20,271.77 |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $27.22 | $22.71 |
| 52 Week High | $43.88 | $48.28 |
Technical Indicators
Market Signals| Indicator | VNT | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 71.16 |
| Support Level | $35.61 | $43.92 |
| Resistance Level | $36.31 | $46.32 |
| Average True Range (ATR) | 0.65 | 2.12 |
| MACD | 0.36 | 0.14 |
| Stochastic Oscillator | 94.83 | 85.75 |
Price Performance
Historical ComparisonAbout VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.